CoChat
Sign Up
Cited by 72Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchHealth Systems, Economic Evaluations, Quality of Life

Expected wait times for access to a disease‐modifying Alzheimer's treatment in the United States

Mattke, Soeren, Hanson, Mark·2022·Alzheimer's & Dementia
DOI 10.1002/alz.12470
Open this paper in CoChat — free account

Abstract

Introduction A 2017 study had analyzed the preparedness of the U.S. health care system to deliver a disease-modifying Alzheimer's treatment and predicted substantial wait times. We update the prediction with an improved model and newer data. Methods The model tracks patients from initial evaluation, cognitive testing by a dementia specialist, confirmatory biomarker testing, and infusion delivery. All steps after initial evaluation are assumed to be capacity constrained. Model parameters and assumptions about care-seeking behavior were derived from the published literature and expert input. Results If patients were referred based on a brief cognitive test, wait times for specialist visits would reach around 50 months. If referral also required a positive blood-based biomarker test, wait times would be around 12 months. In both scenarios, wait times for confirmatory biomarker testing and infusion treatment would be limited. Discussion Better diagnostic tools at initial evaluation may reduce unnecessary delays in access to treatment.

Integrity signals

Registry

Crossref · 10.1002/alz.12470

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Modeling by the RAND Corporation in 2017 showed that with an anti-amyloid therapy for people in the MCI and early dementia stages of the disease, approximately 2.1 million individuals with MCI due to Alzheimer's disease would develop Alzheimer's dementia between 2020 and 2040 while on waiting lists for treatment.

    “modeling by the RAND Corporation in 2017 showed that with an anti‐amyloid therapy for people in the MCI and early dementia stages of the disease, approximately 2.1 million individuals with MCI due to Alzheimer's disease would develop Alzheimer's dementia between 2020 and 2040 while on waiting lists for treatment.”

    From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [973]

  • Capacity constraints, such as a limited number of qualified providers and facilities, could severely restrict access to new treatments.

    “Capacity constraints — such as a limited number of qualified providers and facilities — could severely restrict access to new treatments. 972 , 973”

    From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [973]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mattke, S., & Hanson, M.
Affiliations
University of Southern California (US)
Corresponding author
Mattke, Soeren
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2021-09-27
Volume
18
Issue
5
Pages
1071-1074
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1002/alz.12470
OpenAlex
W3203822095
Cited by
72
References
2
Citations by year
2026: 17 · 2025: 19 · 2024: 16 · 2023: 12 · 2022: 8
FWCI
5.65
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
Alzheimer's disease, disease-modifying therapy
MeSH terms
Alzheimer Disease, Delivery of Health Care, Humans, Referral and Consultation, United States, Waiting Lists, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review